EMA gives green light to Actelion’s Uptravi after safety review|Health Consumer

ZURICH The European Medicines Agency on Friday gave its green light for doctors to continue using Actelion’s Uptravi, saying a review after five patient deaths in France did not suggest an increase in mortality linked to the pulmonary arterial hypertension drug.


Source: EMA gives green light to Actelion’s Uptravi after safety review

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s